LncRNA PVT1调节SOCS2表达对胆管癌细胞增殖的影响
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v7i2.13415
Abstract
目的：本研究旨在探究长链非编码RNA淋巴瘤易位变体1(lncRNA PVT1)和细胞因子信号抑制因子2(SOCS2)在胆管癌(CCA)细胞增殖和迁移中的作用,从而为CCA的发病机制提供新的理论见解。方法：收集2021年10月至2023年11月期间在承德医学院附属医院经手术确诊并经病理诊断的20例胆管癌患者的癌组织及癌旁组织样本。培养正常胆管上皮细胞(HIBEC)和胆管癌细胞系(RBE、HCCC9810、HUCCT1)。采用实时定量逆转录PCR(qRT-PCR)检测lncRNA PVT1的表达。将小干扰RNA(siRNA)转染入HUCCT1细胞以下调lncRNA PVT1的表达。通过细胞计数试剂盒8(CCK-8)检测细胞增殖情况,采用蛋白质印迹法(WB)分析胆管癌组织和细胞中SOCS2的表达水平,以及lncRNA PVT1敲低前后的情况。结果：qRT-PCR显示,CCA组织中 lncRNA PVT1的表达显著高于相邻组织(P<0.05)。在细胞系中,HUCCT1细胞中lncRNA PVT1的表达最高(与HIBEC相比,P<0.0001),且siRNA-PVT1-3的敲低效果最为显著(P<0.0001)。lncRNA PVT1的敲低显著降低了HUCCT1细胞的增殖(P<0.01)和迁移(P<0.0001)。WB 结果表明,CCA组织中SOCS2的表达低于正常组织(P<0.05),而敲低lncRNA PVT1后,SOCS2的表达得以恢复(P<0.0001)。结论：lncRNA PVT1在CCA中表达上调,通过抑制SOCS2促进肿瘤进展。沉默lncRNA PVT1可恢复SOCS2的表达,从而抑制CCA细胞的增殖。
Keywords
胆管癌；非编码RNA；lncRNA PVT1；SOCS2；增殖
Funding
河北省自然科学基金资助项目(H2021406047)；河北省教育厅在读研究生创新能力培养资助项目(CXZZSS2023145)。
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] HARRISON JM, VISSER BC. Cholangiocarcinoma[J]. Surg Clin North Am,2024,104(10):1281-1293.
[2] CIOBICA ML,SANDULESCU BA,CHICEA LM,et al.The Constel lation of Risk Factors and Paraneoplastic Syndromes in Chola ngiocarcinoma: Integrating the Endocrine Panel Amid Tumour -Related Biology(A Narrative Review).Biology (Basel),2024,13(9):662.
[3] CHEN F,SHENG J,LI X,et al.Tumor-associated macrophag es: orchestrators of cholangiocarcinoma progression[J]. Front Immunol,2024,15:1451474.
[4] YI Q, FENG J, LAN W, et al. CircRNA and lncRNA-encoded peptide in diseases, an update review[J].Mol Cancer, 2024,23(1):214.
[5] LI R, WANG X, ZHU C, et al. lncRNA PVT1: a novel oncogene in multiple cancers[J].Cell Mol Biol Lett,2022,27(1):84.
[6] HE M, CAI Y, YUAN Z, et al. Upregulation of SOCS2 causes mitochondrial dysfunction and promotes ferroptosis in pancre atic cancer cells[J].Acta Biochim Pol,2023,70(1):163-168.
[7] WANG JL, JI WW, HUANG AL, et al. CEBPA Restrains the Mal ignant Progression of Breast Cancer by Prompting the Transc ription of SOCS2[J]. Mol Biotechnol. Published online May 22,2024.
[8] ROGALSKA-TARANTA M,ANDERSEN JB.Involvement of Epig enomic Factors in Bile Duct Cancer[J].Semin Liver Dis,2022,42 (2):202-211.
[9] JURKIEWICZ M,SZCZEPANIAK A,ZIELIŃSKA M.Long non-cod ing RNAs-SNHG6 emerge as potential marker in colorectal canc er[J].Biochim Biophys Acta Rev Cancer,2024,1879(1):189056.
[10] RAMACHANDRAN S, MAKUKHIN N,HAUBRICH K,et al.Struct ure-based design of a phosphotyrosine-masked covalent liga nd targeting the E3 ligase SOCS2[J].Nat Commun,2023,14(1): 6345.
[2] CIOBICA ML,SANDULESCU BA,CHICEA LM,et al.The Constel lation of Risk Factors and Paraneoplastic Syndromes in Chola ngiocarcinoma: Integrating the Endocrine Panel Amid Tumour -Related Biology(A Narrative Review).Biology (Basel),2024,13(9):662.
[3] CHEN F,SHENG J,LI X,et al.Tumor-associated macrophag es: orchestrators of cholangiocarcinoma progression[J]. Front Immunol,2024,15:1451474.
[4] YI Q, FENG J, LAN W, et al. CircRNA and lncRNA-encoded peptide in diseases, an update review[J].Mol Cancer, 2024,23(1):214.
[5] LI R, WANG X, ZHU C, et al. lncRNA PVT1: a novel oncogene in multiple cancers[J].Cell Mol Biol Lett,2022,27(1):84.
[6] HE M, CAI Y, YUAN Z, et al. Upregulation of SOCS2 causes mitochondrial dysfunction and promotes ferroptosis in pancre atic cancer cells[J].Acta Biochim Pol,2023,70(1):163-168.
[7] WANG JL, JI WW, HUANG AL, et al. CEBPA Restrains the Mal ignant Progression of Breast Cancer by Prompting the Transc ription of SOCS2[J]. Mol Biotechnol. Published online May 22,2024.
[8] ROGALSKA-TARANTA M,ANDERSEN JB.Involvement of Epig enomic Factors in Bile Duct Cancer[J].Semin Liver Dis,2022,42 (2):202-211.
[9] JURKIEWICZ M,SZCZEPANIAK A,ZIELIŃSKA M.Long non-cod ing RNAs-SNHG6 emerge as potential marker in colorectal canc er[J].Biochim Biophys Acta Rev Cancer,2024,1879(1):189056.
[10] RAMACHANDRAN S, MAKUKHIN N,HAUBRICH K,et al.Struct ure-based design of a phosphotyrosine-masked covalent liga nd targeting the E3 ligase SOCS2[J].Nat Commun,2023,14(1): 6345.
Copyright © 2025 张铁钊, 曹喜东, 张力勇, 羿海钊, 陈凯, 李剑, 白子誉, 于爱军
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
